Indian Januvia challenger Aprica harps on price as MSD takes action
This article was originally published in Scrip
A fledgling Indian company, Aprica Pharmaceuticals, appears to have come close to a potential launch of cut-price versions of MSD's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride) on the Indian market, prompting pre-emptive legal action from the US multinational.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.